Talniflumate (Genaera)

Curr Opin Investig Drugs. 2004 May;5(5):557-62.

Abstract

Talniflumate, an anti-inflammatory molecule that was originally developed by Laboratorios Bago, is currently being developed by Genaera as a mucoregulator for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma. Phase I trials with talniflumate had been completed by August 2001, and phase II trials were underway in Ireland for the treatment of cystic fibrosis.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use*
  • Asthma / drug therapy
  • Benzofurans / adverse effects
  • Benzofurans / pharmacokinetics
  • Benzofurans / therapeutic use*
  • Chloride Channels / drug effects
  • Chloride Channels / metabolism
  • Clinical Trials as Topic
  • Cystic Fibrosis / drug therapy
  • Expectorants / adverse effects
  • Expectorants / pharmacokinetics
  • Expectorants / therapeutic use*
  • Humans
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pyridines / adverse effects
  • Pyridines / pharmacokinetics
  • Pyridines / therapeutic use*
  • Sinusitis / drug therapy
  • Structure-Activity Relationship

Substances

  • Anti-Inflammatory Agents
  • Benzofurans
  • Chloride Channels
  • Expectorants
  • Pyridines
  • talniflumate